Meeting
2021 ASCO Annual Meeting
Interim results of PATHFINDER, a clinical use study using a methylation-based multi-cancer early detection test.
Authors
Tomasz M. Beer
Knight Cancer Institute, Oregon Health & Science University, Portland, OR
Tomasz M. Beer , Charles H. McDonnell III, Lincoln Nadauld , Minetta C. Liu , Eric A. Klein , Robert Lawrence Reid , Catherine Marinac , Karen Chung , Margarita Lopatin , Eric T. Fung , Deborah Schrag
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT04241796
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3010)
DOI
10.1200/JCO.2021.39.15_suppl.3010
Abstract #
3010
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation.
First Author: Tomasz M. Beer
Poster
2024 ASCO Annual Meeting
Polyploid circulating stromal cells in blood to identify invasive solid tumors and to prognosticate for highly aggressive cancer subtypes.
First Author: Daniel L Adams
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Clinical presentation and delay to diagnosis and treatment in Mexican patients with gastric cancer.
First Author: Jorge Humberto Hernandez-Felix
Poster
2023 ASCO Annual Meeting
Laparoscopic versus open-surgery in FIGO stage II endometrioid endometrium cancers: Is there a prognostic effect?
First Author: Daniel Uwe Reimer